{'fraction_non_alphanumeric': 0.02062975027144408, 'fraction_numerical': 0.0054288816503800215, 'mean_word_length': 4.872611464968153, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes.

The article by Home et al. (1) in the May issue of Diabetes Care prompted us to respond and comment on the current practice of reporting on clinical trials when insulin analogs are concerned. While a cure for type 1 diabetes has not yet been achieved, comprehensive, multidisciplinary treatment strategies have lead the way to offer patients and their families a near-normal life and affected children a near-normal life expectancy. Multiple injections, insulin pump therapy, and frequent blood glucose measurements have provided the basis for better quality of life and good metabolic control in people with type 1 diabetes. However, the value of insulin analogs is still in question (2). There is no doubt that industry has invested vast resources to develop new insulin types for safety and efficacy reasons. …